Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

Inhaled Nanosilver Study

Study Background

The goal of the Inhaled Nanosilver Study is to assess the impact of inhaled silver nanoparticles on immune responses in the lung. Due to its antimicrobial properties, there are many consumer products which contain nanosilver, such as cleaning supplies and clothing fabrics. There are also several products on the market that people use to inhale nanosilver dissolved in water, which the manufacturers claim help to boost the immune system. This research study will investigate whether nanosilver affects the function of the lung.

Participants of the Nanosilver Study will have 1 screening visit and 3 study visits. All of the visits will take place at the Clinical Research Unit (CRU) on the National Institute of Environmental Health Sciences (NIEHS) campus in Research Triangle Park.

During the visits, team members will talk to you about your medical history and any medications you take, record vital signs, conduct breathing tests and a physical exam, and collect blood and urine samples from you.  The treatment visit will involve breathing in a solution of nanosilver using a nebulizer, which is a machine that creates a fine mist. Two of the visits will involve a procedure called a bronchoscopy during which cells may be collected from areas of the lung.

Principal Investigator

Stavros Garantziotis, M.D.
Stavros Garantziotis, M.D.
Medical Director, NIEHS Clinical Research Unit and Principal Investigator
Tel 984-287-4412
Fax 919-541-9854
P.O. Box 12233
Mail Drop CU-01
Durham, N.C. 27709
to Top